TScan Therapeutics (TCRX) Total Liabilities (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Total Liabilities data on file, last reported at $105.1 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 14.23% year-over-year to $105.1 million in Q1 2026; TTM through Mar 2026 was $105.1 million, a 14.23% decrease from a year earlier, with the FY2025 full-year figure at $105.7 million, down 18.81% from the prior year.
• Total Liabilities for Q1 2026 stood at $105.1 million, down from $105.7 million in the prior quarter.
• Over the last five years, Total Liabilities for TCRX reached as high as $130.1 million in Q4 2024 and fell as low as $20.8 million in Q2 2022.
• Historically, Total Liabilities has averaged $101.0 million across 5 years, with a median of $118.2 million in 2025.
• Across the five-year window, Total Liabilities slumped 32.2% in 2022 and jumped 508.37% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $99.7 million in 2022, then climbed by 21.7% to $121.3 million in 2023, then grew by 7.31% to $130.1 million in 2024, then declined by 18.81% to $105.7 million in 2025, then fell by 0.56% to $105.1 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $105.1 million in Q1 2026, $105.7 million in Q4 2025, and $118.2 million in Q3 2025.